Abstract

Histone deacetylase (HDAC)-dependent transcriptional repression of the retinoic acid (RA)-signaling pathway underlies the differentiation block of acute promyelocytic leukemia. RA treatment relieves transcriptional repression and triggers differentiation of acute promyelocytic leukemia blasts, leading to disease remission. We report that transcriptional repression of RA signaling is a common mechanism in acute myeloid leukemias (AMLs). HDAC inhibitors restored RA-dependent transcriptional activation and triggered terminal differentiation of primary blasts from 23 AML patients. Accordingly, we show that AML1/ETO, the commonest AML-associated fusion protein, is an HDAC-dependent repressor of RA signaling. These findings relate alteration of the RA pathway to myeloid leukemogenesis and underscore the potential of transcriptional/differentiation therapy in AML.

Keywords

Acute promyelocytic leukemiaMyeloid leukemiaPsychological repressionCancer researchHistone deacetylaseRetinoic acidLeukemiaHDAC1Promyelocytic leukemia proteinTretinoinHistoneMyeloidSignal transductionHistone deacetylase inhibitorBiologyCell biologyImmunologyGeneticsGene expressionGene

Affiliated Institutions

Related Publications

Publication Info

Year
2001
Type
article
Volume
61
Issue
1
Pages
2-7
Citations
240
Access
Closed

External Links

Citation Metrics

240
OpenAlex

Cite This

Francesca Ferrara, Francesco Fazi, Andrea Bianchini et al. (2001). Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.. PubMed , 61 (1) , 2-7.